The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Murray Christopher K. since 2020.
This trader's CIK number is 1718648.
At the time of last reporting, Murray Christopher K. was the CHIEF TECHNICAL OPERATIONS of Blueprint Medicines Corp. (stock ticker symbol BPMC).
Also see all insider trading activities at Blueprint Medicines Corp.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | BPMC | 0 | $0 | 8,142 | $786,785 | 5,000 | $270,650 |
| 2023 | BPMC | 0 | $0 | 8,075 | $536,082 | 5,000 | $270,650 |
| 2022 | BPMC | 0 | $0 | 6,568 | $406,054 | 0 | $0 |
| 2021 | BPMC | 0 | $0 | 1,210 | $106,256 | 0 | $0 |
| 2020 | BPMC | 0 | $0 | 402 | $20,879 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-03-07 | BPMC | Sale | 2,521 | 90.69 | 228,629 |
| 2024-03-04 | BPMC | Sale | 621 | 93.65 | 58,156 |
| 2024-02-28 | BPMC | Option Ex | 5,000 | 54.13 | 270,650 |
| 2024-02-28 | BPMC | Sale | 5,000 | 100.00 | 500,000 |
| 2023-12-07 | BPMC | Option Ex | 5,000 | 54.13 | 270,650 |
| 2023-12-07 | BPMC | Sale | 5,000 | 75.00 | 375,000 |
| 2023-12-04 | BPMC | Sale | 600 | 71.43 | 42,858 |
| 2023-10-26 | BPMC | Sale | 600 | 56.40 | 33,840 |
| 2023-03-06 | BPMC | Sale | 1,875 | 45.01 | 84,384 |
| 2022-08-04 | BPMC | Sale | 2,500 | 60.44 | 151,100 |
| 2022-08-05 | BPMC | Sale | 2,500 | 65.00 | 162,500 |
| 2022-03-03 | BPMC | Sale | 1,066 | 60.27 | 64,247 |
| 2022-03-07 | BPMC | Sale | 502 | 56.19 | 28,207 |
| 2021-03-04 | BPMC | Sale | 1,210 | 87.81 | 106,256 |
| 2020-03-09 | BPMC | Sale | 402 | 51.94 | 20,879 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Murray Christopher K. (CHIEF TECHNICAL OPERATIONS of Blueprint Medicines Corp at the time of this reporting) see the Securities and Exchange Commission (SEC) website.